{"protocolSection": {"identificationModule": {"nctId": "NCT00882518", "orgStudyIdInfo": {"id": "D1444C00008"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients", "officialTitle": "A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode", "acronym": "ESPRIT"}, "statusModule": {"statusVerifiedDate": "2012-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-04"}, "primaryCompletionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-04-14", "studyFirstSubmitQcDate": "2009-04-15", "studyFirstPostDateStruct": {"date": "2009-04-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-03-07", "resultsFirstSubmitQcDate": "2012-04-16", "resultsFirstPostDateStruct": {"date": "2012-05-15", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-04-16", "lastUpdatePostDateStruct": {"date": "2012-05-15", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode."}, "conditionsModule": {"conditions": ["Schizophrenia"], "keywords": ["Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "qualified PANSS assessment"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 388, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "type": "EXPERIMENTAL", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) extended-release (300 mg/1st day, 600 mg/2nd day, 400 or 600 or 800 mg/3-42 day)", "interventionNames": ["Drug: Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)"]}, {"label": "2-Chlorpromazine", "type": "ACTIVE_COMPARATOR", "description": "Chlorpromazine (50 or 100 mg/1st day; 100-200 mg/2nd day; 150-300 mg/3rd day; 200-400 mg/4th day; 300 or 400 or 500 or 600 mg/5-42 days)", "interventionNames": ["Drug: Chlorpromazine"]}], "interventions": [{"type": "DRUG", "name": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "200 mg or 300 mg, oral, single dose", "armGroupLabels": ["1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)"], "otherNames": ["Seroquel_XR (Quetiapine Fumarate XR)"]}, {"type": "DRUG", "name": "Chlorpromazine", "description": "50 mg, oral, double dose", "armGroupLabels": ["2-Chlorpromazine"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline.PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7. Total scores range 30-210 from better to worse.", "timeFrame": "Baseline and 6 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in PANSS Positive Subscale Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7. 1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Change From Baseline in PANSS Negative Subscale Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7. 1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme The PANSS negative subscale score is the sum of the 7 item scores (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking), ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Change From Baseline in PANSS General Psychopathological Subscale Score at the End of Treatment at Day 42", "description": "The PANSS psychopathological subscale score is the sum of 16 item scores(somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, active social avoidance), ranges from 16 to 112. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Change From Baseline in PANSS Aggression, Hostility Clusters Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7 (better to worse).\n\n1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Change From Baseline in PANSS Depression Clusters Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7 (better to worse).\n\n1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Number of Patients Achieving a Reduction of at Least 30% From Baseline PANSS Total Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7 (better to worse).Total scores range 30-210 from better to worse.\n\n1 =Absent,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme.", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Percentage of Patients With Clinical Global Impression (CGI) Global Improvement Rating Less Than or Equal to 3 at the End of Treatment at Day 42", "description": "6 weeks minus baseline. The number of patients with CGI Global Improvement (CGI-I) rating at least \"minimally improved\" at the end of treatment at Day 42 was counted, and then got the proportion among all the patients.CGI-I is scored to rate the patient's change from baseline CGI on a seven-point scale (1=\"Very much improved\", 7=\"Very much worse\".)", "timeFrame": "Baseline and 6 weeks"}, {"measure": "Change in the CGI Severity of Illness Score From Baseline at the End of Treatment at Day 42", "description": "6 weeks minus baseline The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale rating the severity of the patient's illness. The patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.", "timeFrame": "Baseline and 6 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Schizophrenia diagnosis\n* Provision of written informed consent before initiation of any study\n\nExclusion Criteria:\n\n* AIDS and hepatitis B\n* History of seizure disorder\n* Hospitalisation for schizophrenic more than 1 month immediately before enter into study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Niufan Gu", "affiliation": "Shanghai Mental Health Center", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Michael Castiglione", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Hunan", "state": "Changsha", "country": "China"}, {"facility": "Research Site", "city": "Guangzhou", "state": "Guangdong", "country": "China", "geoPoint": {"lat": 23.11667, "lon": 113.25}}, {"facility": "Research Site", "city": "Baoding", "state": "Hebei", "country": "China", "geoPoint": {"lat": 38.85111, "lon": 115.49028}}, {"facility": "Research Site", "city": "Ha Er Bin", "state": "Heilongjiang", "country": "China"}, {"facility": "Research Site", "city": "Wuhan", "state": "Hubei", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "Research Site", "city": "Changsha", "state": "Hunan", "country": "China", "geoPoint": {"lat": 28.19874, "lon": 112.97087}}, {"facility": "Research Site", "city": "Nanjing", "state": "Jiangsu", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Research Site", "city": "Xi'an", "state": "Shanxi", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "Research Site", "city": "Kunming", "state": "Yunnan", "country": "China", "geoPoint": {"lat": 25.03889, "lon": 102.71833}}, {"facility": "Research Site", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Research Site", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "388 patients from 11 sites were randomised into Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) group or chlorpromazine group.", "groups": [{"id": "FG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "FG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "196"}, {"groupId": "FG001", "numSubjects": "192"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "158"}, {"groupId": "FG001", "numSubjects": "148"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "38"}, {"groupId": "FG001", "numSubjects": "44"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "18"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "13"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "9"}]}, {"type": "Severe non-compliance to protocol", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Incorrect enrolment", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Central lab closure for National day", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Allocating random number by mistake", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Seroquel_XR", "description": "Quetiapine fumarate XR was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion. Full analysis set (FAS) population used for baseline characteristics"}, {"id": "BG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion. Full analysis set (FAS) population used for baseline characteristics"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "194"}, {"groupId": "BG001", "value": "190"}, {"groupId": "BG002", "value": "384"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"title": "age", "categories": [{"measurements": [{"groupId": "BG000", "value": "32.9", "spread": "10.70"}, {"groupId": "BG001", "value": "32.0", "spread": "10.33"}, {"groupId": "BG002", "value": "32.5", "spread": "10.52"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "100"}, {"groupId": "BG002", "value": "202"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "182"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline.PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7. Total scores range 30-210 from better to worse.", "populationDescription": "Per-protocol population was used as the analysis set for primary outcome, because this is a non-inferior design study.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "159"}, {"groupId": "OG001", "value": "150"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-33.4", "spread": "1.45", "lowerLimit": "1.45"}, {"groupId": "OG001", "value": "-35.9", "spread": "1.35", "lowerLimit": "1.35"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in PANSS Positive Subscale Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7. 1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme The PANSS positive subscale score is the sum of the 7 positive item scores (ie, delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution and hostility) and ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.9", "spread": "0.53", "lowerLimit": "0.53"}, {"groupId": "OG001", "value": "-11.1", "spread": "0.51", "lowerLimit": "0.51"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in PANSS Negative Subscale Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7. 1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme The PANSS negative subscale score is the sum of the 7 item scores (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking), ranges from 7 to 49. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.9", "spread": "0.5", "lowerLimit": "0.50"}, {"groupId": "OG001", "value": "-6.7", "spread": "0.48", "lowerLimit": "0.48"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in PANSS General Psychopathological Subscale Score at the End of Treatment at Day 42", "description": "The PANSS psychopathological subscale score is the sum of 16 item scores(somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation, active social avoidance), ranges from 16 to 112. A negative change (or decrease) from baseline indicates a reduction (or improvement) in symptoms.", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-12.9", "spread": "0.74", "lowerLimit": "0.74"}, {"groupId": "OG001", "value": "-13.9", "spread": "0.71", "lowerLimit": "0.71"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in PANSS Aggression, Hostility Clusters Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7 (better to worse).\n\n1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.8", "spread": "0.33", "lowerLimit": "0.33"}, {"groupId": "OG001", "value": "-5.4", "spread": "0.32", "lowerLimit": "0.32"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in PANSS Depression Clusters Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7 (better to worse).\n\n1 =Absent ,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "0.18", "lowerLimit": "0.18"}, {"groupId": "OG001", "value": "-1.7", "spread": "0.18", "lowerLimit": "0.18"}]}]}]}, {"type": "SECONDARY", "title": "Number of Patients Achieving a Reduction of at Least 30% From Baseline PANSS Total Score at the End of Treatment at Day 42", "description": "6 weeks minus baseline PANSS scale is a 30-item scale where each symptom is rated on a severity scale ranging from 1-7 (better to worse).Total scores range 30-210 from better to worse.\n\n1 =Absent,2 =Minimal, 3 =Mild, 4 =Moderate, 5 =Moderate severe, 6 =Severe, 7= Extreme.", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.7"}, {"groupId": "OG001", "value": "66.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients With Clinical Global Impression (CGI) Global Improvement Rating Less Than or Equal to 3 at the End of Treatment at Day 42", "description": "6 weeks minus baseline. The number of patients with CGI Global Improvement (CGI-I) rating at least \"minimally improved\" at the end of treatment at Day 42 was counted, and then got the proportion among all the patients.CGI-I is scored to rate the patient's change from baseline CGI on a seven-point scale (1=\"Very much improved\", 7=\"Very much worse\".)", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.6"}, {"groupId": "OG001", "value": "88.9"}]}]}]}, {"type": "SECONDARY", "title": "Change in the CGI Severity of Illness Score From Baseline at the End of Treatment at Day 42", "description": "6 weeks minus baseline The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale rating the severity of the patient's illness. The patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.", "populationDescription": "Full analysis set was used for secondary outcome", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "scores on a scale", "timeFrame": "Baseline and 6 weeks", "groups": [{"id": "OG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion."}, {"id": "OG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "194"}, {"groupId": "OG001", "value": "190"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.8", "spread": "0.12", "lowerLimit": "0.12"}, {"groupId": "OG001", "value": "-2.1", "spread": "0.11", "lowerLimit": "0.11"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)", "description": "Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) was administered orally, once daily in the evening. The initial dose was 300 mg. This dose was adjusted on Day 2 to 600 mg, from Day 3 to Day 42, the dose of Quetiapine fumarate XR could be adjusted at 400 mg/day, 600 mg/day, or 800 mg/day at the investigator's discretion.", "seriousNumAffected": 0, "seriousNumAtRisk": 196, "otherNumAffected": 142, "otherNumAtRisk": 196}, {"id": "EG001", "title": "Chlorpromazine", "description": "Chlorpromazine was administered orally, twice daily. The initial dose was 50 mg to 100 mg. This dose was adjusted on Day 2 from 100 to 200 mg, on Day 3 from 150 to 300 mg, and Day 4 from 200 to 400 mg. From Day 5, the dose of chlorpromazine could be adjusted at 300 mg/day, 400 mg/day, 500 mg/day, or 600 mg/day at the investigator's discretion.", "seriousNumAffected": 2, "seriousNumAtRisk": 192, "otherNumAffected": 166, "otherNumAtRisk": 192}], "seriousEvents": [{"term": "Suicide Attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 192}]}, {"term": "Grand Mal Convulsion", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 192}]}], "otherEvents": [{"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 49, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 192}]}, {"term": "Extrapyramidal Disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 58, "numAtRisk": 192}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 27, "numAtRisk": 192}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 192}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 24, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 21, "numAtRisk": 192}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 192}]}, {"term": "Upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 192}]}, {"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 192}]}, {"term": "Tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 192}]}, {"term": "Heart rate increased", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 192}]}, {"term": "Orthostatic Hypotension", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 18, "numAtRisk": 192}]}, {"term": "Hepatic Function Abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 9, "numAtRisk": 192}]}, {"term": "Somnolence", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 192}]}, {"term": "Nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 13, "numAtRisk": 192}]}, {"term": "Akathisia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.0", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 196}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 192}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Gerard Lynch", "organization": "AstraZeneca", "email": "aztrial_results_posting@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26"}, "conditionBrowseModule": {"meshes": [{"id": "D000012559", "term": "Schizophrenia"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}], "browseLeaves": [{"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M14473", "name": "Psychotic Disorders", "relevance": "LOW"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000002746", "term": "Chlorpromazine"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000932", "term": "Antiemetics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000005765", "term": "Gastrointestinal Agents"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Retraction", "relevance": "HIGH"}, {"id": "M5987", "name": "Chlorpromazine", "asFound": "Tivozanib", "relevance": "HIGH"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M4251", "name": "Antiemetics", "relevance": "LOW"}, {"id": "M8881", "name": "Gastrointestinal Agents", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnEm", "name": "Antiemetics"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}